All In Biotech

Free tool

FAERS Monitor: Neostigmine Methylsulfate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203629 or its brand name (Neostigmine Methylsulfate, Neostigmine Methylsulfate). Reports on generic versions are filed under their own applications.

Reports

365

Serious

331

91% of reports

Hospitalization

156

Death reported

53

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective34
  • abdominal distension25
  • nausea23
  • hypotension22
  • respiratory failure20
  • abdominal pain19
  • white blood cell count increased18
  • cardiac arrest16
  • pyrexia16
  • bradycardia15
  • generalised tonic-clonic seizure15
  • subileus15
  • febrile neutropenia14
  • pulmonary oedema14
  • renal ischaemia14

Reports by year received

View as table
YearReports
20055
20066
20073
20084
20096
20105
20113
201216
20139
201416
201511
201623
201719
201825
201926
202020
202120
202229
202334
202445
202529
202611

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,794 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
renal ischaemiaSignal141515.1900.219,193
subileusSignal15418.2254.35,791
generalised tonic-clonic seizureSignal1552.331.8704
white blood cell count increasedSignal1827.117.2426
pulmonary oedemaSignal1418.010.8209
bradycardiaSignal1516.39.9201
respiratory failureSignal2015.810.3264
abdominal distensionSignal2513.89.5286
febrile neutropeniaSignal1412.27.3133
cardiac arrestSignal1611.26.9139
hypotensionSignal226.34.294
abdominal painSignal194.73.052
pyrexiaSignal162.71.715
nausea231.71.16
drug ineffective341.51.15

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.